Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis

Ear, Nose and Throat Journal

Volumn 82, Issue 8, 2003, Pages 576-590

  Luterman, Maynard ^a   Tellier, Guy ^a   Lasko, Benjamin ^a   Leroy, Bruno ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; METRONIDAZOLE; TELITHROMYCIN;

ABDOMINAL PAIN; ADULT; ALLERGY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROENTERITIS; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXILLA SINUSITIS; MULTICENTER STUDY; NAUSEA; PSEUDOMEMBRANOUS COLITIS; RANDOMIZED CONTROLLED TRIAL; VAGINA CANDIDIASIS; VERTIGO;

EID: 0042475649     PISSN: 01455613     EISSN: None     Source Type: Journal    
DOI: 10.1177/014556130308200812     Document Type: Article

References (24)

1. Gwaltney JM, Jr. Acute community acquired bacterial sinusitis: To treat or not to treat. Can Respir J 1999;6(Suppl A):46A-50A.
2. Youngs R. Sinusitis in adults. Curr Opin Pulm Med 2000;6: 217-20.
3. Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1997. Vital Health Stat 13 1999;(143):i-iv, 1-39.
4. Parsons DS, Wald ER. Otitis media and sinusitis: Similar diseases. Otolaryngol Clin North Am 1996;29:11-25.
5. Ahuja GS, Thompson J. What role for antibiotics in otitis media and sinusitis? Postgrad Med 1998;104(3):93-9, 103-4.
6. Bartlett JG. IDCP guidelines: Management of upper respiratory tract infections. Infect Dis Clin Pract 1997;6:212-20.
7. Felmingham D, Gruneberg RN. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45:191-203.
8. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect Agents Dis 1994;3:266-73.
9. Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998;42:624-30.
10. Dubois J, St. Pierre C. In vitro study of the minimal inhibitory concentrations (MIC) of telithromycin (HMR 3647), macrolides and quinolones against Haemophilus, Streptococcus, Staphylococcus and Moraxella strains obtained from upper and lower respiratory tract infections and from maxillary sinus aspiration. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 17-20, 2000; Toronto.
11. Agouridas C, Bonnefoy A, Chantot JF. In vitro antibacterial activity of HMR 3647, a novel ketolide highly active against respiratory pathogens. Presented at the 4th International Conference on Macrolides, Azalides, Streptogramins and Ketolides; Jan. 21-23, 1998; Barcelona.
12. Biedenbach DJ, Barrett MS, Jones RN. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. Diagn Microbiol Infect Dis 1998;31:349-53.
13. Jacobs MR, Bajaksouzian S, Zilles A, et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother 1999;43:1901-8.
14. Lenfant B, Sultan E, Wable C, et al. Pharmacokinetics of 800 mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 24-27, 1998; San Diego.
15. Miyamoto N, Murakami S, Yajin K, et al. Pharmacokinetic study of a new ketolide antimicrobial telithromycin (HMR 3647) in otorhinolaryngology. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 17-20, 2000; Toronto.
16. Brook I, Gooch WM III, Jenkins SG, et al. Medical management of acute bacterial sinusitis: Recommendations of a clinical advisory committee on pediatric and adult sinusitis. Ann Otol Rhinol Laryngol 2000;109:2-20.
17. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis 1997;29:249-57.
18. Roos K, Brunswig-Pitschner C, Kostrica R, et al. Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy 2002;48:100-8.
19. Camacho AE, Cobo R, Otte J, et al., Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with acute bacterial maxillary sinusitis. Am J Med 1992;93:271-6.
20. Calhoun KH, Hokanson JA. Multicenter comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Arch Fam Med 1993;2:837-40.
21. Gwaltney JM, Jr., Savolainen S, Rivas P, et al. Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Cefdinir Sinusitis Study Group. Antimicrob Agents Chemother 1997;41:1517-20.
22. Von Sydow C, Savolainen S, Soderqvist A. Treatment of acute maxillary sinusitis - comparing cefpodoxime proxetil with amoxicillin. Scand J Infect Dis 1995;27:229-34.
23. Sydnor A, Jr., Gwaltney JM, Jr., Cocchetto DM, Scheld WM. Comparative evaluation of cefuroxime axetil and cefaclor for treatment of acute bacterial maxillary sinusitis. Arch Otolaryngol Head Neck Surg 1989;115:1430-3.
24. Sydnor TA, Kopp EJ, Anthony KE, et al. Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults. Ann Allergy Asthma Immunol 1998;80:357-62.